Po Kan Mak

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.